Last reviewed · How we verify
Anti-Arrhythmic therapy
Blocks potassium channels to prevent arrhythmias
Blocks potassium channels to prevent arrhythmias Used for Supraventricular tachycardia, Ventricular tachycardia, Ventricular fibrillation.
At a glance
| Generic name | Anti-Arrhythmic therapy |
|---|---|
| Also known as | Amiodarone, Dronaderone, Sotalol, Beta blockers, Calcium channel blockers |
| Sponsor | Imperial College London |
| Drug class | Class I anti-arrhythmic |
| Target | Potassium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Mechanism of action
Anti-arrhythmic drugs work by blocking potassium channels in the heart, which helps to regulate the heart's rhythm and prevent arrhythmias.
Approved indications
- Supraventricular tachycardia
- Ventricular tachycardia
- Ventricular fibrillation
Common side effects
- QT interval prolongation
- Torsades de pointes
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Acupuncture for Preventing Atrial Arrhythmia Recurrence After Ablation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (NA)
- Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-Arrhythmic therapy CI brief — competitive landscape report
- Anti-Arrhythmic therapy updates RSS · CI watch RSS
- Imperial College London portfolio CI